An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Four deaths cast doubt on J&J’s multi-pronged KLK2 push.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.